Biogen Inc. (BIIB)

• Annual Data
• Quarterly Data

Biogen Inc., Common-Size Consolidated Income Statement

	12 months ended	Dec 31, 2018		Dec 31, 2017		Dec 31, 2016		Dec 31, 2015		Dec 31, 2014
	Product, net
	Revenues from anti-CD20 therapeutic programs
	Other
	Revenues
	Cost of sales, excluding amortization and impairment of acquired intangible assets
	Gross profit
	Research and development
	Selling, general and administrative
	Amortization and impairment of acquired intangible assets
	Collaboration profit sharing
	Acquired in-process research and development
	Restructuring charges
	Gain (loss) on fair value remeasurement of contingent consideration
	TECFIDERA litigation settlement charge
	Gain on sale of rights
	Income from operations
	Interest income
	Interest expense
	Gain (loss) on investments, net
	Foreign exchange gains (losses), net
	Other, net
	Other income (expense), net
	Income before income tax expense and equity in loss of investee, net of tax
	Income tax expense
	Equity in loss of investee, net of tax
	Net income
	Net (income) loss attributable to noncontrolling interests, net of tax
	Net income attributable to Biogen Inc.

Based on: 10-K (filing date: 2019-02-06), 10-K (filing date: 2018-02-01), 10-K (filing date: 2017-02-02), 10-K (filing date: 2016-02-03), 10-K (filing date: 2015-02-04).